Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
Everything NICE has said on neurological conditions in an interactive flowchart
syndrome - azacitidine 1 June 2010 TBC Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) 30 September 2016 TA494...
In development [GID-TAG507] Expected publication date: TBC
NICE block scoping reports
Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta
NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.